9th Floor, Empire Heights Tower A, Shuraa Gold Business Centre , Business Bay 79998 Dubai AE
JollyRX
9th Floor, Empire Heights Tower A, Shuraa Gold Business Centre , Business Bay Dubai, AE
+971585996347 //cdn1.storehippo.com/s/6052eead9e1cf8aa024c48c8/606ecab786617735b12707ae/webp/jollyrx-480x480.png" contact@jollyrx.com
61b4813aa12858d7878858b2 VENCLYXTO 100 MG 112 TABLET //cdn1.storehippo.com/s/6052eead9e1cf8aa024c48c8/61b4812da12858d78788574f/webp/venclyxto-100-mg-112-tablet.jpg

VENCLYXTO 100 MG 112 TABLET

Combination with obinutuzumab for the treatment of adult patients with untreated chronic lymphocytic leukemia (CLL). Concomitant use with rituximab for the treatment of adult patients with CLL who have received at least one pretreatment. As monotherapy for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for B cell receptor pathway inhibitors or who have failed B cell receptor pathway inhibitors. Also as monotherapy for the treatment of CLL without 17p deletion or TP53 mutation in adult patients who have failed both chemimmune therapy and B cell receptor pathway inhibitors.

Oral. Treatment should be initiated and supervised by a physician who has experience with anticancer drugs. Patients treated with venetoclax may develop Tumor Lysis Syndrome (TLS). To prevent and reduce the risk of TLS, you need to follow risk assessments, precautions, dose escalation schedules, laboratory monitoring, and drug interactions. See SmPC for more information.

Dosage:

The starting dose for dose escalation is 20 mg venetoclax once daily for 7 days.

Vomiting, nausea, constipation, malaise. Common side effects (1/10 urinary tract infections, febrile neutropenia, TLS, hyperuricemia, and increased blood creatinine. Note that some of these effects were also observed at grade ≥3. Serious adverse reactions: The most commonly reported serious adverse reactions (≥2%) in patients receiving venetoclax monotherapy were pneumonia and febrile neutropenia. In combination with obinutuzumab or rituximab, we reported pneumonia, sepsis, febrile neutropenia, and TLS, which were the most commonly serious adverse reactions (≥2%).

SKU-Z7QRM3SNC5FN
in stockINR
1 1
VENCLYXTO 100 MG 112 TABLET

VENCLYXTO 100 MG 112 TABLET


Product Enquiry

Sold By: jollyrx
VARIANTSELLERPRICEQUANTITY

Description of product

VENCLYXTO 100 MG 112 TABLET

Combination with obinutuzumab for the treatment of adult patients with untreated chronic lymphocytic leukemia (CLL). Concomitant use with rituximab for the treatment of adult patients with CLL who have received at least one pretreatment. As monotherapy for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for B cell receptor pathway inhibitors or who have failed B cell receptor pathway inhibitors. Also as monotherapy for the treatment of CLL without 17p deletion or TP53 mutation in adult patients who have failed both chemimmune therapy and B cell receptor pathway inhibitors.

Oral. Treatment should be initiated and supervised by a physician who has experience with anticancer drugs. Patients treated with venetoclax may develop Tumor Lysis Syndrome (TLS). To prevent and reduce the risk of TLS, you need to follow risk assessments, precautions, dose escalation schedules, laboratory monitoring, and drug interactions. See SmPC for more information.

Dosage:

The starting dose for dose escalation is 20 mg venetoclax once daily for 7 days.

Vomiting, nausea, constipation, malaise. Common side effects (1/10 urinary tract infections, febrile neutropenia, TLS, hyperuricemia, and increased blood creatinine. Note that some of these effects were also observed at grade ≥3. Serious adverse reactions: The most commonly reported serious adverse reactions (≥2%) in patients receiving venetoclax monotherapy were pneumonia and febrile neutropenia. In combination with obinutuzumab or rituximab, we reported pneumonia, sepsis, febrile neutropenia, and TLS, which were the most commonly serious adverse reactions (≥2%).

User reviews

  0/5